{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:46:02Z","timestamp":1790171162889,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:00:00Z","timestamp":1562371200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T00:00:00Z","timestamp":1562371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00432-019-02971-7","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T10:04:09Z","timestamp":1562407449000},"page":"2365-2373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study"],"prefix":"10.1007","volume":"145","author":[{"given":"Alessandro","family":"Parisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":false,"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Dell\u2019Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Stellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Alberto","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zoratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mazzuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Porzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Ficorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Cannita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,6]]},"reference":[{"issue":"12","key":"2971_CR1","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB et al (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol 17(12):1697\u20131708","journal-title":"Lancet Oncol"},{"issue":"3","key":"2971_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10147-017-1089-y","volume":"22","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T et al (2017) Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II\/III gastric cancer. Int J Clin Oncol. 22(3):476\u2013483. https:\/\/doi.org\/10.1007\/s10147-017-1089-y (Epub 2017 Feb 7)","journal-title":"Int J Clin Oncol."},{"issue":"9742","key":"2971_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemoterapy versus chemoterapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"1","key":"2971_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12957-016-1076-1","volume":"15","author":"S Chen","year":"2017","unstructured":"Chen S, Nie RC, OuYang LY, Li YF, Xiang J, Zhou ZW et al (2017) Body mass index (BMI) may be a prognostic factor for gastric cancer with peritoneal dissemination. World J Surg Oncol. 15(1):52. https:\/\/doi.org\/10.1186\/s12957-016-1076-1","journal-title":"World J Surg Oncol."},{"issue":"2","key":"2971_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3892\/or.2018.6475","volume":"40","author":"A Cortellini","year":"2018","unstructured":"Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B et al (2018) Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: a single institution experience with the FD\/FOx regimen. Oncol Rep 40(2):803\u2013812. https:\/\/doi.org\/10.3892\/or.2018.6475 (Epub 2018 Jun 6)","journal-title":"Oncol Rep"},{"key":"2971_CR6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"74","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc (Series B) 74:187\u2013200","journal-title":"J R Stat Soc (Series B)"},{"issue":"1","key":"2971_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa073149","journal-title":"N Engl J Med"},{"issue":"2","key":"2971_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11523-018-0562-5","volume":"13","author":"M Di Bartolomeo","year":"2018","unstructured":"Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM et al (2018) Ramucirumab as second-line therapy in metastatic gastric cancer: real-world data from the RAMoss study. Target Oncol. 13(2):227\u2013234. https:\/\/doi.org\/10.1007\/s11523-018-0562-5","journal-title":"Target Oncol."},{"issue":"3","key":"2971_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10120-015-0541-9","volume":"19","author":"SM Ebinger","year":"2016","unstructured":"Ebinger SM, Warschkow R, Tarantino I, Schmied BM, G\u00fcller U, Schiesser M (2016) Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer 19(3):723\u2013734. https:\/\/doi.org\/10.1007\/s10120-015-0541-9 (Epub 2015 Sep 21)","journal-title":"Gastric Cancer"},{"key":"2971_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"issue":"1","key":"2971_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jss.2014.12.048","volume":"195","author":"A Ejaz","year":"2015","unstructured":"Ejaz A, Spolverato G, Kim Y, Poultsides GA, Fields RC, Bloomston M et al (2015) Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. J Surg Res 195(1):74\u201382. https:\/\/doi.org\/10.1016\/j.jss.2014.12.048 (Epub 2014 Dec 31)","journal-title":"J Surg Res"},{"issue":"7","key":"2971_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.ejca.2014.01.029","volume":"50","author":"A Ferro","year":"2014","unstructured":"Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F et al (2014) Worldwide trends in gastric cancer mortality (1980\u20132011), with predictions to 2015, and incidence by subtype. Eur J Cancer 50(7):1330\u20131344. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.029 (Epub 2014 Mar 17)","journal-title":"Eur J Cancer"},{"key":"2971_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339","journal-title":"Lancet"},{"issue":"2","key":"2971_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5230\/jgc.2017.17.e16","volume":"17","author":"CS Fuchs","year":"2017","unstructured":"Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC et al (2017) Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer. 17(2):132\u2013144","journal-title":"J Gastric Cancer."},{"issue":"11","key":"2971_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1046\/j.1365-2168.2002.02220.x","volume":"89","author":"HH Hartgrink","year":"2002","unstructured":"Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ, Dutch Gastric Cancer Group (2002) Value of palliative resection in gastric cancer. Br J Surg. 89(11):1438\u20131443","journal-title":"Br J Surg."},{"issue":"1","key":"2971_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.15403\/jgld.2014.1121.251.rv2","volume":"25","author":"K Izuishi","year":"2016","unstructured":"Izuishi K, Mori H (2016) Recent strategies for treating stage IV gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis. 25(1):87\u201394. https:\/\/doi.org\/10.15403\/jgld.2014.1121.251.rv2","journal-title":"J Gastrointestin Liver Dis."},{"key":"2971_CR17","doi-asserted-by":"publisher","first-page":"CD004063","DOI":"10.1002\/14651858.cd004063.pub4","volume":"11","author":"VT Janmaat","year":"2017","unstructured":"Janmaat VT, Steyerberg EW, Van Der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP et al (2017) Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 11:CD004063. https:\/\/doi.org\/10.1002\/14651858.cd004063.pub4","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"2971_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/01635581.2016.1224363","volume":"68","author":"DH Jun","year":"2016","unstructured":"Jun DH, Kim BJ, Park JH, Kim JG, Chi KC, Park JM et al (2016) Preoperative body mass index may determine the prognosis of advanced gastric cancer. Nutr Cancer. 68(8):1295\u20131300 (Epub 2016 Oct 7)","journal-title":"Nutr Cancer."},{"issue":"5","key":"2971_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10120-018-0806-1","volume":"21","author":"M Jung","year":"2018","unstructured":"Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG et al (2018) Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer 21(5):819\u2013830. https:\/\/doi.org\/10.1007\/s10120-018-0806-1 (Epub 2018 Feb 9)","journal-title":"Gastric Cancer"},{"key":"2971_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2971_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5230\/jgc.2017.17.e12","volume":"17","author":"KH Kim","year":"2017","unstructured":"Kim KH, Park DJ, Park YS, Ahn SH, Park DJ, Kim HH (2017) Actual 5-year nutritional outcomes of patients with gastric cancer. J Gastric Cancer. 17(2):99\u2013109. https:\/\/doi.org\/10.5230\/jgc.2017.17.e12 (Epub 2017 May 23)","journal-title":"J Gastric Cancer."},{"issue":"9","key":"2971_CR22","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.21873\/anticanres.12860","volume":"38","author":"S Komatsu","year":"2018","unstructured":"Komatsu S, Kosuga T, Kubota T, Okamoto K, Konishi H, Shiozaki A et al (2018) Preoperative low weight affects long-term outcomes following curative gastrectomy for gastric cancer. Anticancer Res 38(9):5331\u20135337. https:\/\/doi.org\/10.21873\/anticanres.12860","journal-title":"Anticancer Res"},{"issue":"2","key":"2971_CR23","first-page":"807","volume":"36","author":"H Kubo","year":"2016","unstructured":"Kubo H, Komatsu S, Ichikawa D, Kawaguchi T, Kosuga T, Okamoto K et al (2016) Impact of body weight loss on recurrence after curative gastrectomy for gastric cancer. Anticancer Res 36(2):807\u2013813","journal-title":"Anticancer Res"},{"issue":"10","key":"2971_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ejso.2010.07.007","volume":"36","author":"J Kulig","year":"2010","unstructured":"Kulig J, Sierzega M, Kolodziejczyk P, Dadan J, Drews M, Fraczek M (2010) Implications of overweight in gastric cancer: a multicenter study in a Western patient population. Eur J Surg Oncol 36(10):969\u2013976. https:\/\/doi.org\/10.1016\/j.ejso.2010.07.007 (Epub 2010 Aug 21)","journal-title":"Eur J Surg Oncol"},{"issue":"114","key":"2971_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5754\/hge11415","volume":"59","author":"SE Lee","year":"2012","unstructured":"Lee SE, Lee JH, Ryu KW, Nam B, Kim CG, Park SR et al (2012) Changing pattern of postoperative body weight and its association with recurrence and survival after curative resection for gastric cancer. Hepatogastroenterology. 59(114):430\u2013435. https:\/\/doi.org\/10.5754\/hge09218","journal-title":"Hepatogastroenterology."},{"key":"2971_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejca.2015.10.061","volume":"52","author":"HH Lee","year":"2016","unstructured":"Lee HH, Park JM, Song KY, Choi MG, Park CH (2016) Survival impact of postoperative body mass index in gastric cancer patients undergoing gastrectomy. Eur J Cancer 52:129\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2015.10.061 (Epub 2015 Dec 10)","journal-title":"Eur J Cancer"},{"issue":"8","key":"2971_CR27","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s11605-013-2238-x","volume":"17","author":"YS Lin","year":"2013","unstructured":"Lin YS, Huang KH, Lan YT, Fang WL, Chen JH, Lo SS et al (2013) Impact of body mass index on postoperative outcome of advanced gastric cancer after curative surgery. J Gastrointest Surg. 17(8):1382\u20131391. https:\/\/doi.org\/10.1007\/s11605-013-2238-x (Epub 2013 May 29)","journal-title":"J Gastrointest Surg."},{"issue":"10","key":"2971_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725\u2013730","journal-title":"N Engl J Med"},{"issue":"1","key":"2971_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-018-4057-7","volume":"18","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H et al (2018) A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer. 18(1):120. https:\/\/doi.org\/10.1186\/s12885-018-4057-7","journal-title":"BMC Cancer."},{"issue":"49","key":"2971_CR30","first-page":"284","volume":"50","author":"Y Moriwaki","year":"2003","unstructured":"Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kasaoka C (2003) Does body mass index (BMI) influence morbidity and long-term survival in gastric cancer patients after gastrectomy? Hepatogastroenterology. 50(49):284\u2013288","journal-title":"Hepatogastroenterology."},{"issue":"1","key":"2971_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10147-017-1192-0","volume":"23","author":"S Murahashi","year":"2018","unstructured":"Murahashi S, Takahari D, Wakatsuki T, Fukuda N, Ichimura T, Ogura M et al (2018) A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int J Clin Oncol. 23(1):92\u201397. https:\/\/doi.org\/10.1007\/s10147-017-1192-0 (Epub 2017 Sep 14)","journal-title":"Int J Clin Oncol."},{"issue":"2","key":"2971_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10120-015-0481-4","volume":"19","author":"CY Ock","year":"2016","unstructured":"Ock CY, Oh DY, Lee J, Kim TY, Lee KH, Han SW et al (2016) Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer 19(2):597\u2013606. https:\/\/doi.org\/10.1007\/s10120-015-0481-4 (Epub 2015 Mar 8)","journal-title":"Gastric Cancer"},{"issue":"8","key":"2971_CR33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1158\/1055-9965.EPI-18-0122","volume":"27","author":"YS Park","year":"2018","unstructured":"Park YS, Park DJ, Lee Y, Park KB, Min SH, Ahn SH et al (2018) Prognostic roles of perioperative body mass index and weight loss in the long-term survival of gastric cancer patients. Cancer Epidemiol Biomark Prev 27(8):955\u2013962. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0122 (Epub 2018 May 21)","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"2971_CR34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10120-018-0796-z","volume":"21","author":"AS Paulson","year":"2018","unstructured":"Paulson AS, Hess LM, Liepa AM, Cui ZL, Aguilar KM, Clark J et al (2018) Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer 21(5):831\u2013844. https:\/\/doi.org\/10.1007\/s10120-018-0796-z (Epub 2018 Feb 3)","journal-title":"Gastric Cancer"},{"key":"2971_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1997","unstructured":"Schemper M, Smith TL (1997) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343\u2013346","journal-title":"Control Clin Trials"},{"issue":"33","key":"2971_CR36","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/JCO.2015.60.7465","volume":"33","author":"MA Shah","year":"2015","unstructured":"Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S et al (2015) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 33(33):3874\u20133879","journal-title":"J Clin Oncol"},{"issue":"3","key":"2971_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/01635581.2017.1267774","volume":"69","author":"K Takayoshi","year":"2017","unstructured":"Takayoshi K, Uchino K, Nakano M, Ikejiri K, Baba E (2017) Weight loss during initial chemotherapy predicts survival in patients with advanced gastric cancer. Nutr Cancer 69(3):408\u2013415. https:\/\/doi.org\/10.1080\/01635581.2017.1267774 (Epub 2017 Jan 19)","journal-title":"Nutr Cancer"},{"issue":"10060","key":"2971_CR38","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388(10060):2654\u20132664. https:\/\/doi.org\/10.1016\/S0140-6736(16)30354-3 (Epub 2016 May 5)","journal-title":"Lancet"},{"key":"2971_CR39","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"issue":"13","key":"2971_CR40","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouch\u00e9 O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715\u20131721. https:\/\/doi.org\/10.1200\/JCO.2010.33.0597 (Epub 2011 Mar 28)","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02971-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T18:00:25Z","timestamp":1721498425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02971-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,6]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2971"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02971-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,6]]},"assertion":[{"value":"28 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Alessio Cortellini received grants as speaker by MSD, Astra-Zeneca and Boehringer Ingelheim, gran consultancies by BMS, Roche, Novartis, Istituto Gentili and Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided informed consent to participate in this observational non-interventional study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The procedures followed were in accordance with the precepts of Good Clinical Practice and the Declaration of Helsinki. The study was conducted following the rules of the local bioethical committee competent on human experimentation (Comitato etico per le province di L\u2019Aquila e Teramo).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}